Avraham Pharmaceuticals

Company Overview

Snapshot

Founded in February 2010 by Michael Horev, Marta Weinstock-Rosin, and Moussa B.H. Youdim, Avraham Pharmaceuticals operates with 1–10 employees. The company raised a total of $26.2 million across 5 funding rounds from 5 investors. In February 2016, the company closed an additional investment round.

Business overview

Avraham Pharmaceuticals is a pharmaceutical company focused on developing novel products for the treatment and prevention of neurodegenerative disorders, including Alzheimer's disease, Lewy body disease, and Parkinson's disease. The company's core product candidate, Ladostigil, was in-licensed from the Hebrew University and the Technion. Ladostigil is a multifunctional compound designed to reduce oxidative stress and microglial activation while inhibiting pro-inflammatory cytokines, with the potential to slow the progression of Alzheimer's disease in patients with mild cognitive impairment (MCI). Avraham Pharmaceuticals operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.

Strategic signal

In July 2014, Avraham Pharmaceuticals reported positive. This milestone is significant as it provides clinical validation for the company's therapeutic approach to neurodegenerative disorders, suggesting potential efficacy in slowing the progression of conditions like Alzheimer's disease. For investors, this indicates progress in clinical development and de-risking of the asset, potentially opening pathways for further investment or partnership opportunities in the pharmaceutical market.

Company Intelligence Q&A

What is Avraham Pharmaceuticals' primary focus?

Avraham Pharmaceuticals is focused on developing novel products for the treatment and prevention of neurodegenerative disorders such as Alzheimer's disease, Lewy body disease, and Parkinson's disease.

What is the status of Avraham Pharmaceuticals' lead product candidate?

Avraham Pharmaceuticals' lead product candidate, Ladostigil, is in Phase 2 clinical studies for mild cognitive impairment (MCI).

When did Avraham Pharmaceuticals report positive Phase IIb results for Ladostigil?

In July 2014, Avraham Pharmaceuticals reported positive Phase IIb results for Ladostigil in the treatment of mild cognitive impairment.

Which institutions did Avraham Pharmaceuticals license its lead product from?

Avraham Pharmaceuticals exclusively in-licensed its lead product candidate, Ladostigil, from the Hebrew University and the Technion.

Which investors participated in Avraham Pharmaceuticals' February 2016 funding round?

In February 2016, Avraham Pharmaceuticals closed an additional investment round with participation from.